BioCentury | Apr 30, 2007
Strategy

MedImmune chronicles

...Receives an exclusive license to a TIRC7 program in preclinical development for immunological diseases from GenPat77...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...life sciences. Biotech companies in its portfolio include therapeutic aptamer company Noxxon and autoimmune company GenPat77...
BioCentury | Dec 11, 2006
Company News

GenPat77, Charite University of Medicine deal

...topoisomerase inhibitor has completed a pilot study in neuroblastoma patients. Further terms were not disclosed. GenPat77 Pharmacogenetics AG...
BioCentury | Aug 28, 2006
Company News

GenPat77, Medarex deal

...GenPat77. The companies will share product development and commercialization responsibilities. Financial terms were not disclosed. GenPat77 Pharmacogenetics AG...
BioCentury | Aug 23, 2006
Company News

Medarex, GenPat77 autoimmune deal

...use its UltiMab Human Antibody Development System to generate antibodies against autoimmune disease targets from GenPat77...
BioCentury | Apr 24, 2006
Regulation

The TeGenero impact

...the 1990s saying that CD28 mediates activation of T cells," noted Nalan Utku, CEO of GenPat77 Pharmacogenetics AG...
BioCentury | Sep 19, 2005
Strategy

MedImmune deal flow

...Medarex 11/23/04 Partners to develop two preclinical MEDX antibodies, MDX-1103 and MDX-1333, for autoimmune diseases GenPat77...
BioCentury | Apr 11, 2005
Company News

GenPat77 board of directors update

GenPat77 Pharmacogenetics AG , Berlin, Germany Business: Autoimmune, Inflammation, Transplant Appointed: Metin Colpan, former CEO of Qiagen N.V. WIR Staff autoimmune Inflammation Transplant...
BioCentury | Feb 28, 2005
Finance

MedImmune Ventures activity

...CRTX) Series B $56.0 Y Inotek Series A $20.0 N Iomai Series C $56.0 N GenPat77...
BioCentury | Oct 11, 2004
Tools & Techniques

Selective suppression

...treatment of many immune diseases, as overall suppression usually makes patients vulnerable to opportunistic infections. GenPat77 Pharmacogenetics AG...
...transmembrane protein that was discovered 10 years ago by Nalan Utku, president and CEO of GenPat77...
...it might serve as a useful early diagnostic and prognostic biomarker, e.g., for transplant rejection." GenPat77...
Items per page:
1 - 10 of 12
BioCentury | Apr 30, 2007
Strategy

MedImmune chronicles

...Receives an exclusive license to a TIRC7 program in preclinical development for immunological diseases from GenPat77...
BioCentury | Apr 9, 2007
Finance

Ebb & Flow

...life sciences. Biotech companies in its portfolio include therapeutic aptamer company Noxxon and autoimmune company GenPat77...
BioCentury | Dec 11, 2006
Company News

GenPat77, Charite University of Medicine deal

...topoisomerase inhibitor has completed a pilot study in neuroblastoma patients. Further terms were not disclosed. GenPat77 Pharmacogenetics AG...
BioCentury | Aug 28, 2006
Company News

GenPat77, Medarex deal

...GenPat77. The companies will share product development and commercialization responsibilities. Financial terms were not disclosed. GenPat77 Pharmacogenetics AG...
BioCentury | Aug 23, 2006
Company News

Medarex, GenPat77 autoimmune deal

...use its UltiMab Human Antibody Development System to generate antibodies against autoimmune disease targets from GenPat77...
BioCentury | Apr 24, 2006
Regulation

The TeGenero impact

...the 1990s saying that CD28 mediates activation of T cells," noted Nalan Utku, CEO of GenPat77 Pharmacogenetics AG...
BioCentury | Sep 19, 2005
Strategy

MedImmune deal flow

...Medarex 11/23/04 Partners to develop two preclinical MEDX antibodies, MDX-1103 and MDX-1333, for autoimmune diseases GenPat77...
BioCentury | Apr 11, 2005
Company News

GenPat77 board of directors update

GenPat77 Pharmacogenetics AG , Berlin, Germany Business: Autoimmune, Inflammation, Transplant Appointed: Metin Colpan, former CEO of Qiagen N.V. WIR Staff autoimmune Inflammation Transplant...
BioCentury | Feb 28, 2005
Finance

MedImmune Ventures activity

...CRTX) Series B $56.0 Y Inotek Series A $20.0 N Iomai Series C $56.0 N GenPat77...
BioCentury | Oct 11, 2004
Tools & Techniques

Selective suppression

...treatment of many immune diseases, as overall suppression usually makes patients vulnerable to opportunistic infections. GenPat77 Pharmacogenetics AG...
...transmembrane protein that was discovered 10 years ago by Nalan Utku, president and CEO of GenPat77...
...it might serve as a useful early diagnostic and prognostic biomarker, e.g., for transplant rejection." GenPat77...
Items per page:
1 - 10 of 12